Ownership and insider activity for Entrada Therapeutics, Inc. (TRDA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
Price
| Price | $6.89 |
| Market Cap | $267M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.8M | $39.0M | $291.1M | $45.2M | $67.6M | $101.2M | $90.4M |
| Short-term Investments | 0 | 0 | 0 | $143.6M | $284.4M | $318.8M | $205.3M |
| Receivables | 0 | 0 | 0 | 0 | $5.9M | $3.7M | $2.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $17.4M | $39.9M | $298.7M | $209.9M | $369.8M | $440.0M | $306.3M |
| Property, Plant & Equipment | $801000 | $3.0M | $6.3M | $33.0M | $92.7M | $82.0M | $67.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $18.2M | $43.5M | $305.8M | $252.1M | $469.2M | $526.3M | $377.4M |
| Accounts Payable | $710000 | $1.6M | $706000 | $6.0M | $3.3M | $4.3M | $2.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.9M | $3.4M | $6.7M | $22.0M | $158.8M | $39.5M | $24.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $33.8M | $85.0M | $7.1M | $39.5M | $226.8M | $97.6M | $71.2M |
| Retained Earnings | -$16.0M | -$42.5M | -$93.7M | -$188.3M | -$195.0M | -$129.3M | -$273.1M |
| Total Equity | -$15.5M | -$41.5M | $298.7M | $212.6M | $242.4M | $428.7M | $306.1M |
| Total Debt | 0 | 0 | 0 | $25.9M | $68.2M | $59.2M | $50.9M |
| Net Debt | -$16.8M | -$39.0M | -$291.1M | -$162.8M | -$283.7M | -$360.8M | -$244.8M |
| Working Capital | $15.5M | $36.6M | $292.0M | $187.9M | $211.0M | $400.6M | $281.8M |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 10.89 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 2.17 |
Profitability
| Return on Equity | -57.61% |
| Return on Invested Capital | -62.61% |
| Return on Assets | -55.47% |
| Gross Margin | -754.72% |
| Operating Margin | -3767.07% |
| Net Margin | -3537.73% |
Related companies: ACHV · ALLO · ARCT · AVIR · CAPR · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of TRDA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks